GlobeNewswire Inc | Dec 1, 2021 04:05PM EST

December 01, 2021

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference. Details are as follows:

4th Annual Evercore ISI HealthCONx ConferenceDate: December 2, 2021Time: 12:10-12:30 p.m. ET

A webcast of the virtual presentation will be available on the Investors & Media section of the Codiak website at https://ir.codiakbio.com/. Archived replays will be available for approximately 30 days following the event.

About Codiak BioSciencesCodiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential totransformthe treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platformto expand upon the innate properties of exosomes to design, engineer and manufacturenovel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipelineof engineered exosomes aimed attreatingabroad rangeof diseases, spanning oncology, neuro-oncology, infectious disease and rare disease.

Investor Contact:Christopher TaylorVP, Investor Relations and Corporate Communications T: 617-949-4220E: investor@codiakbio.com

Media Contact:Lindy DevereuxScient PRT: 646-515-5730E:lindy@scientpr.com